Article Information
History
- January 9, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Dr Ravikirti, Additional Professor and Head1,*,
- Dr Ranjini Roy, Postgraduate Trainee2,
- Dr Chandrima Pattadar, Postgraduate Trainee2,
- Dr Rishav Raj, Postgraduate Trainee3,
- Dr Neeraj Agarwal, Professor and Head4,
- Dr Bijit Biswas, Senior Resident5,
- Dr Pramod Kumar Majhi, Assistant Professor and Head6,
- Dr Deependra Kumar Rai, Additional Professor and Head7,
- Dr Shyama, Assistant Professor3,
- Dr Anjani Kumar, Assistant Professor3 and
- Dr Asim Sarfaraz, Assistant Professor9
- 1Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India
- 2Department of General Medicine, AIIMS, Patna, India
- 3Department of General Medicine, AIIMS, Patna
- 4Department of Community and Family Medicine, AIIMS, Bibi Nagar, India
- 5Department of Community and Family Medicine, AIIMS, Patna, India
- 6Department of Pharmacology, AIIMS, Patna, India
- 7Department of Pulmonary Medicine, AIIMS, Patna, India
- 9Department of Microbiology, AIIMS, Patna
- ↵*Corresponding Author
Dr Ravikirti, Additional Professor and Head, Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India, Email: drravikirti{at}aiimspatna.org, Phone: 0091-9572424447
Posted January 09, 2021.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
